Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study-Reference-Cited by-同舟云学术

Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study

Published:2021-12 Issue: Volume:361 Page:577746
ISSN:0165-5728
Container-title:Journal of Neuroimmunology
language:en
Short-container-title:Journal of Neuroimmunology

Author:

Achiron Anat,Mandel Mathilda,Dreyer-Alster Sapir,Harari Gil,Dolev Mark,Menascu Shay,Magalashvili David,Flechter Shlomo,Givon Uri,Guber Diana,Sonis Polina,Zilkha-Falb Rina,Gurevich Michael

Funder

Tel Aviv University Sackler Faculty of Medicine

Publisher

Elsevier BV

Subject

Clinical Neurology,Neurology,Immunology,Immunology and Allergy

Reference15 articles.

1. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies;Achiron;Ther. Adv. Neurol. Disord.,2021

2. Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies;Ahmed;Viruses,2020

3. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy;Apostolidis;Nat. Med.,2021

4. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination;Barros-Martins;Nat. Med.,2021

5. Covid-19 breakthrough infections in vaccinated health care workers;Bergwerk;N Engl J Med.,2021

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Human RP105 monoclonal antibody enhances antigen-specific antibody production in unique culture conditions;iScience;2024-09

2. Analysis of Evusheld safety and efficacy in multiple sclerosis patients;Multiple Sclerosis and Related Disorders;2024-08

3. Tixagevimab/Cilgavimab does not prevent COVID-19 in patients with multiple sclerosis and related disorders on B-cell depleting therapies;Multiple Sclerosis and Related Disorders;2024-07

4. Humoral immune response and safety of Sars-Cov-2 vaccine in people with multiple sclerosis;BMC Immunology;2024-06-19

5. Sphingosine 1‐phosphate receptor modulators in multiple sclerosis treatment: A practical review;Annals of Clinical and Translational Neurology;2024-02-16